UFP Technologies Inc (UFPT) Stock Analysis
Verdict: WATCH (do not buy)
Record medtech EPS beats and Intuitive deal growth justify strength, but heavy insider selling and full valuation limit short-term upside.
Investment score: 58/100
Analysis as of
Is UFP Technologies Inc stock worth reviewing? The TradeMates thesis
The TradeMates model rates UFP Technologies (UFPT) as a WATCH. While underlying operational execution is strong—driven by medical device demand and expanding supply contracts with Intuitive Surgical—the stock's 31.75x TTM P/E multiple leaves little room for expansion. Furthermore, significant insider selling across executive leadership signals that current valuations fully reflect near-term earnings growth.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 78/100 (weight 15%)
- Technical Momentum: 72/100 (weight 15%)
- Earnings Quality: 82/100 (weight 15%)
- Insider Sentiment: 25/100 (weight 10%)
- Analyst Consensus: 55/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
UFP Technologies Inc opportunities and risks
What speaks for UFPT
- Supply Agreement Expansion with Intuitive Surgical
What speaks against UFPT
- Product and Customer Concentration Volatility
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| UFPT | 31.8x | 3.6x | 20.9x | 28.5% | 11.4% | 2.7% |
| MMED | n/a | 1.6x | 29.1x | 53.8% | -10.2% | -6.2% |
| ICUI | 139.4x | 1.9x | 20.8x | 37.6% | 1.4% | 3.7% |
| QDEL | n/a | 0.4x | n/a | 44.6% | -39.2% | -22.1% |
| XRAY | n/a | 0.5x | 41.2x | 49.5% | -15.0% | 8.1% |
| NEOG | n/a | 3.0x | 31.2x | 47.4% | -6.3% | 1.9% |
| Peer median | n/a | 1.6x | 29.1x | 47.4% | -10.2% | 1.9% |
Frequently asked questions about UFP Technologies Inc (UFPT)
Is UFPT stock a good investment?
The TradeMates model rates UFP Technologies Inc as WATCH (do not buy) with an investment score of 58/100. The TradeMates model rates UFP Technologies (UFPT) as a WATCH. While underlying operational execution is strong—driven by medical device demand and expanding supply contracts with Intuitive Surgical—the stock's 31.75x TTM P/E multiple leaves little room for expansion. Furthermore, significant insider selling across executive leadership signals that current valuations fully reflect near-term earnings growth. This is algorithmic model output, not personal investment advice.
Is UFPT stock a buy?
The TradeMates model verdict for UFPT is WATCH (do not buy) with an investment score of 58/100. Treat this as a model signal to review, not a personal buy recommendation.